Piramal Pharma’s Q1FY25 result was driven by better traction in innovative CDMO portfolio (50% of CDMO sales). Q1 is a seasonally weak quarter due to which its margins (10.5% in Q1FY25 vs 20.8% in Q4FY24) are volatile.